CRH and breast carcinoma: Regarding fatal MACEs, patients with pathological stage-II breast cancer in the CH group had a significantly lower IPTW-HR(0.729, 95% CI: 0.533–0.997); and those in the CRH group patients also had a significantly lower IPTW-HR (0.598, 95% CI: 0.427–0.837) (Table 5).